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A better understanding of the biological evolution of gliomas and its modulation by 
therapeutic interventions has become a central topic 1,2. However, little is known 
about the natural evolution of glioblastoma treated by surgery alone. Glioblastoma 
patients are almost always treated with radiotherapy or chemotherapy, and if not, 
rarely undergo second surgery. 
Here, we report a series of five glioblastoma patients, who did not undergo treatment 
beyond surgery, but had second surgery for recurrent disease after a median of 66 
days (range 36-128 days; patient 1, 128 days; patient 2, 66 days; patient 3, 95 days; 
patient 4, 36 days; patient 5, 38 days). Reasons included patient wish (patients 1, 2, 
3) or early progression detected during radiotherapy planning (patients 4, 5). All 
patients had gross total resection at first surgery followed by another gross total 
(patients 1, 3, 4) or partial resection (<99%) (patients 2, 5) at recurrence. Median age 
at diagnosis was 63 years (range 50-72 years). Three patients were included in a 
previous study 2. This study was approved by the Ethics Committee of the Canton of 
Zurich. 
All tumors were histologically classic glioblastomas, isocitrate dehydrogenase (IDH)-
wildtype 3. Fig. 1A shows representative histological features of primary and 
recurrent tumors, focusing on vital tumor areas with microvascular proliferation. 
There were no differences in cellularity, predominant cell types and presence of 
necrosis or microvascular proliferation. Comparison of molecular profiles by gene 
panel sequencing 4 revealed few differences between primary and recurrent 
specimens (Fig. 1B). O6-methylguanine DNA methyltransferase (MGMT) promoter 
methylation status did not change. DNA methylation profiling revealed IDH-wildtype 
glioblastoma methylation class family tumors of the receptor tyrosine kinase I (RTK 
I), RTK II and mesenchymal (MES) subclasses 5. Longitudinal methylation profiles 
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were available from two patients, indicating a change in DNA methylation subclass in 
patient 1 from RTK II at initial surgery to RTK I at recurrence, while primary and 
recurrent tumors of patient 4 were both assigned to RTK II (Fig. 1B). Copy number 
variations (CNVs) slightly differed between primary and recurrent tumors in two 
patients with amplification of the cyclin-dependent kinase 4 (CDK4) gene at 
recurrence in patient 1, and homozygous deletion of cyclin-dependent kinase 
inhibitor 2 (CDKN2A) found only in the initial biopsy from patient 3. Finally, 
differences in single nucleotide variations were seen in the tumor from patient 4, 
where a mutation in the epidermal growth factor receptor (EGFR) gene was detected 
in the recurrence. In addition, tumor tissue from patient 5 showed a mutation in the 
neurofibromatosis 1 (NF1) gene at diagnosis but not recurrence (Fig. 1B). Except for 
these two cases, molecular profiles remained stable, as also exemplified in the CNV 
profiles in both the initial tumor and recurrence from patient 4 (Fig. 1C), which are 
typical for glioblastoma, IDH-wildtype. Representative neuroimaging scans from 
patient 4 at diagnosis and recurrence are shown in Fig. 1D.  
Thus, histopathological features, DNA copy number profiles and driver gene 
alterations remain remarkably stable from primary to recurrent glioblastoma in 
patients treated by gross total resection alone. Overall, these findings differ from 
longitudinal studies of glioblastomas treated with cytotoxic therapy, which frequently 
reveal more pronounced molecular changes at tumor recurrence, including 
temozolomide-induced hypermutation in a subset 1,2,6-8. Thus, therapy likely 
modulates the molecular evolution in glioblastoma. Admittedly, the time interval 
between surgeries in our series was short compared with other studies 1,2,6-8. Still, a 
better understanding of molecular changes in response to specific treatments, 
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including radiotherapy, alkylating chemotherapy and immunotherapy may aid clinical 
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Fig 1. Histopathological characteristics, DNA methylation subclasses and 
mutational profiles, and exemplary neuroimaging features of primary (PT) and 
recurrent tumors (RT) of the five glioblastoma patients (1-5). (A) Representative 
histological features in vital tumor areas of the five pairs of PT (left side) and RT 
(right side); scale bars, 50 µm. (B) Graphic representation of the results obtained by 
DNA methylation profiling and next generation sequencing of a glioma-associated 
gene panel. Assignments to molecular subgroups as well as absence or presence of 
the listed aberrations are indicated in color codes as illustrated below the figure. (C) 
Example of copy number plots calculated from DNA methylation array data of PT 
and RT of patient 4; results for chromosome 1-22, X and Y are shown with the p-arm 
(left) and the q-arm (right) separated by dotted lines; gains/amplifications represent 
positive (green), losses negative (red) deviations from the baseline. (D) Axial T1-
weighted gadolinium- enhanced MRI scans of patient 4 with newly diagnosed tumor 
(day 1) and recurrent tumor (day 34) are shown; surgery was performed at day 2 and 
day 38; gross total resection after first surgery was confirmed with contrast-
enhanced CT. 
Abbreviations: amp., amplification; CCDN2, cyclin D2; CDK4, cyclin-dependent 
kinase 4; CDKN2A, cyclin-dependent kinase inhibitor 2; chr, chromosome; CNV, 
copy number variation; del. rear., deletion rearrangement; EGFR, epidermal growth 
factor receptor; EGFRvIII, variant III of EGFR; hom.del., homozygous deletion; M, 
methylated; MES, mesenchymal; MGMT, O6-methylguanine DNA methyltransferase; 
n.a., not available; NF1, neurofibromin 1; PIK3CA, phosphoinositide-3-kinase; PTEN, 
phosphatase and tensin homolog; PTPN11, protein tyrosine phosphatase non-
receptor type 11; RTK, receptor tyrosine kinase; SNV, single nucleotide variation; 
N-O-D-20-00816R1 
 8 
TERT, telomerase reverse transcriptase; TP53, tumor protein 53; UM, unmethylated; 
wt, wildtype. 

